📝 Abstract

In adults with a body mass index of ≥ 30 kg/m2 without diabetes, 2.4 mg of subcutaneous semaglutide weekly with lifestyle intervention led to a sustained, clinically relevant body weight reduction over 68 weeks compared to placebo. We review the study design and results of the STEP 1 trial in this "Bottom Line Summary" for the Evidence-Based Medicine Task Force.

Project Details

🗂 Categories:

🚩 Project Title:

Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss

📖 Publication Date:

March 1, 2022